FirsthandHealth
medRxiv PreprintsInternational20 November 2026

CIRCULATING IMMUNE DYNAMICS DURING NEOADJUVANT CHEMOIMMUNOTHERAPY IN EARLY TRIPLE-NEGATIVE BREAST CANCER

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background: Pathological complete response (pCR) after pembrolizumab-based neoadjuvant chemoimmunotherapy predicts improved outcomes in early triple-negative breast cancer (TNBC), but circulating immune determinants of response remain poorly characterized. Methods: The study included 64 patients with early TNBC treated with pembrolizumab-based neoadjuvant chemoimmunotherapy. Flow cytometry analyzed 125 peripheral-blood specimens collected at baseline, during treatment and before surgery. Baseline PBMCs from 22 patients underwent scRNA-seq, generating 135,271 quality-controlled cells. Analyses
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.